A tumour-associated cell-surface glycoprotein accompanying p53 overexpression and higher growth potential for gastric cancer

Maehara, Yoshihiko; Okuyama, Tomoko; Kakeji, Yoshihiro; Endo, Kazuya; Yamamoto, Manabu; Sugimachi, Keizō

doi:10.1038/bjc.1995.192

Cited by 19 publications

(13 citation statements)

References 26 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In esophageal cancer, there is no association between patient survival and p53 overexpression [25, 26, 33, 34]. However, most articles demonstrate that the p53-positive group shows worse survival in gastric cancer [27, 28, 35, 36]. We need a careful evaluation of p53 overexpression in colon cancer, since completely opposite results are often reported.…”

Section: Discussionmentioning

confidence: 99%

The Difference in p53 Mutations between Cancers of the Upper and Lower Gastrointestinal Tract

et al. 2009

View full text Add to dashboard Cite

Background:p53 gene mutations have been reported in over half of all human cancers and they appear to occur in the early stage of cancer, thus indicating the important role that such mutations may play in the carcinogenesis of the digestive tract. This study investigated the differences in p53 abnormalities between cancers of the upper and lower gastrointestinal tract. Materials and Methods: The DNA of 354 specimens of gastrointestinal cancer (esophagus 85, stomach 112, colon 157) was extracted and then p53 gene mutations were investigated by direct sequencing; the loss of heterozygosity was also synchronously analyzed in all cases. Results: (1) p53 gene mutation: p53 gene mutations were found in 41 samples (48.2%) in the esophagus, 18 samples (16.0%) in the stomach and 36 samples (22.9%) in the colon. p53 mutations were more frequently identified in well-differentiated cancers and a close correlation was recognized between p53 mutations and loss of heterozygosity. (2) Mutation spectrum: the ratio of transversion was 43.9% in esophagus, 33.3% in stomach and 25.0% in the colon tumors. Reciprocally, the ratio of transition was 31.7, 66.7, and 72.2%, respectively. Discussion: The frequency of p53 transversion mutations was extremely high in the upper digestive tract, whereas transition mutations were more frequently observed in the lower digestive tract. The investigation of the spectrum of mutations in p53 is therefore expected to lead to a better understanding of the agents responsible for inducing cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

The Difference in p53 Mutations between Cancers of the Upper and Lower Gastrointestinal Tract

et al. 2009

View full text Add to dashboard Cite

show abstract

“…(B) Survival time for p53-positive patients (n = 115) was shorter than for p53-negative patients (n = 138) in those in the node-positive group (P = 0.0060). Solid line, p53-negative patients; light line, p53-positive patients The p53 abnormal staining was reported to be related to the proliferating activity of cancer cells (Kakeji et al, 1993), and aggressive behaviour of cancer cells for serosal invasion, lymph node metastasis of gastric cancer and a poorer prognosis ensued (Martin et al, 1992;Starzynska et al, 1992;Joypaul et al, 1994;Maehara et al, 1995;Mšnig et al, 1997). Because vascular and lymphatic involvement are closely related to p53 expression, p53 expression was closely related to tumour invasion and metastasis and, in particular, proved to be a significant prognostic factor for node-positive cases.…”

Section: Figurementioning

confidence: 99%

Prognostic value of p53 protein expression for patients with gastric cancer – a multivariate analysis

et al. 1999

Self Cite

View full text Add to dashboard Cite

Mutations in the p53 gene, one of the most common genetic alterations in human cancer, are implicated in tumorigenesis and tumour progression. Although p53 protein expression appears to be correlated to prognosis in patients with malignancy, its prognostic role in gastric cancer has remained controversial. We examined the clinical significance of p53 overexpression in 427 patients with gastric cancer, using multivariate analysis. Tumour sections of gastric cancer tissues from these 427 Japanese patients were stained immunohistochemically with monoclonal antibody PAb1801. The presence of p53 expression was statistically compared with clinicopathological features and post-operative survival, using univariate and multivariate analyses. p53 expression was detected in 38.6% (165 out of 427) of these gastric cancers and immunoreactivity was not observed in normal mucosa adjacent to the tumour. A higher rate of p53 detection was observed among large tumours and in those with a prominent depth of invasion, lymphatic and vascular invasion and lymph node involvement. Prognosis was significantly worse for patients with p53-positive-staining tumours. The 5-year survival rate was 62.5% for patients with p53-negative tumours and 43.3% for those with positive malignancies. p53 expression was a significant prognostic factor for node-positive gastric cancers in subjects undergoing treatment with curative resection, as assessed by Cox regression analysis. Thus, the expression of p53 was closely related to the potential for tumour advance and a poorer post-operative prognosis for patients with gastric cancer. © 1999 Cancer Research Campaign

show abstract

“…The loss of p53 function is related to the progression of the tumor by allowing cells with damaged DNA to continue to multiply (23). In some studies, p53 expression in stomach cancer has been reported to be bad prognosis (9)(10)(11)(12)(13)(14), but other reports have shown that p53 expression has no effect on clinical results (24)(25)(26). The reasons for these conflicting results are unclear.…”

Section: Discussion Discussionmentioning

confidence: 43%

“…Mutation in the p53 gene is one of the most common genetic lesions associated with gastric cancer, and some studies have reported that the expression of p 53 is related to bad prognosis (9)(10)(11)(12)(13)(14).…”

Section: Introduction Introductionmentioning

confidence: 99%

A Pilot Multicenter Study Evaluating the Expression of p53 and ki-67 in Gastric Tumors and Their Utility for Guiding Treatment Strategy

Baek¹,

Kim²,

Kim³

et al. 2017

SGO

View full text Add to dashboard Cite

Background: p53 mutation is the most common genetic alteration in cancers and influences clinical progression. Ki-67 protein is a cellular marker for proliferation in cancer or premalignant lesion. The aim of this study is to investigate whether p53 and Ki-67 measurements in gastric tumors would be helpful in determining treatment strategy. Methods: Immunohistochemical staining using monoclonal antibodies to p53 and Ki-67 was performed on specimens from 29 gastric adenomas (GA) by endoscopic submucosal dissection (ESD) and 240 gastric cancers (GC) by ESD or gastrectomy. Tumor cells with nuclear p53 and Ki-67 protein expression were arbitrarily graded into four groups: < 10 % = negative, 10-30 % = 1+, 30-60 % = 2+, and > 60 % = 3+. Results: The mean tumor sizes in the GA and GC groups were 17.3 ± 11.4 mm and 32.0 ± 20.9 mm respectively (P < 0.001). p53 positivity was not different between the GA and GC groups (P = 0.149), but Ki-67 positivity was significantly different between the 2 groups (P = 0.001). In addition, Ki-67 positivity tended to be increased as the pathologic progression changed from adenoma to cancer. Conclusions: Ki-67 positivity grade seems to be correlated with malignancy potential. Even if endoscopic biopsy showed low grade dysplasia, in lesions with high Ki-67 positivity, it is better to consider active ESD rather than just long-term follow up.

show abstract

A tumour-associated cell-surface glycoprotein accompanying p53 overexpression and higher growth potential for gastric cancer

Cited by 19 publications

References 26 publications

The Difference in p53 Mutations between Cancers of the Upper and Lower Gastrointestinal Tract

The Difference in p53 Mutations between Cancers of the Upper and Lower Gastrointestinal Tract

Prognostic value of p53 protein expression for patients with gastric cancer – a multivariate analysis

A Pilot Multicenter Study Evaluating the Expression of p53 and ki-67 in Gastric Tumors and Their Utility for Guiding Treatment Strategy

Contact Info

Product

Resources

About